Houston space health nonprofit launches first experiments onboard Blue Origin mission

all aboard

Houston-based health tech organization had experiments on Blue Origin's last mission. Photo courtesy of Blue Origin

Houston's Translational Research Institute for Space Health, or TRISH, conducted cutting-edge research onboard Blue Origin's New Shepard rocket that launched Friday, November 22.

The NS-28 mission sent private astronauts on an 11-minute suborbital journey past the recognized boundary of space known as the Kármán line, according to Blue Origin's website. While on board, astronauts wore a medical-grade BioButton device, known as a BioIntelliSense, that monitored vital signs and biometric readings.

The findings will add to TRISH's Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program and were the first data sets captured from a suborbital flight.

“This initiative enables TRISH to further our research in space medicine by collecting valuable human health data,” Jimmy Wu, TRISH deputy director and chief engineer and assistant professor at Baylor, said in a statement. “New data from suborbital flights builds our understanding of how the human body responds to spaceflight. This holistic view is key in keeping humans healthy and safe in space.”

The experiments were also TRISH's first on a Blue Origin mission.

TRISH, which is part of BCM’s Center for Space Medicine with partners Caltech and MIT, has launched experiments on numerous space missions to date, with each contributing to its EXPAND platform, which compiles research on human health while in space.

In January, TRISH launched six experiments onboard Houston-based Axiom Space's third private astronaut mission to the International Space Station, known as Ax-3. Prior to that, it also sent experiments on board the Ax-2 in May 2023. The research considered topics ranging from changes in astronauts memory before and after space travel to sleep and motor skills.

TRISH also launched experiments onboard SpaceX's Polaris Dawn mission this fall and on the Inspiration4 all-civilian mission to orbit in 2021.

TRISH published its findings from the Inspiration4 mission in the journal Nature this summer. The study showed that "short-duration missions do not pose a significant health risk" to humans onboard. Read more about the team's findings here.

From Your Site Articles
Houston Methodist has entered into an agreement with a medical device company. Photo via globenewswire.com

Houston hospital taps health tech company for remote monitoring and analytics partnership

hi, tech

A Houston health care system has announced a new partnership with a medical device company that specializes in continuous health monitoring and clinical intelligence.

Houston Methodist and Colorado-based BioIntelliSense announced a new collaboration to advance remote monitoring and analytics from in-hospital to at-home. BioIntelliSense’s technology includes its FDA-cleared BioSticker and medical grade BioButton. The two devices are wearable and, when paired with algorithmic-based data services, the technologies enable remote data capture and continuous monitoring of over 20 biometrics — up to 1,440 sets of vital sign measurements daily —for up to 30 days on a single device.

“This new strategic collaboration with BioIntelliSense exemplifies Houston Methodist’s continued commitment to advancing world-class expertise and greater efficiency to deliver the highest quality and most impactful care,” says Dr. Sarah Pletcher, vice president and executive medical director of strategic innovation at Houston Methodist, in a news release. “This collaboration keeps the patient at the center as we continue to maximize our leadership in healthcare innovation.”

The two entities executed Memorandum of Understanding that identifies several areas of strategic focus for improving patient care, increasing clinical workflow efficiencies, and reducing the burden on healthcare systems. BioIntelliSense and Houston Methodist will work together to develop a state-of-the-art virtual care control center at Houston Methodist.

“Data-driven remote patient monitoring that is simple, clinically accurate, and cost-effective, is the future of healthcare delivery,” says James Mault, MD, Founder and CEO of BioIntelliSense. “We are proud to work alongside our partners at Houston Methodist to pioneer a continuous care model that provides actionable data and clinical intelligence to enable our overburdened healthcare workforce take better care of patients in any care setting.”

According to the news release, the MOU further establishes the use of leading biosensor technology and the development of advanced algorithms, care models, and data analytics for monitoring and treating a range of complex conditions spanning heart and vascular, orthopedics, oncology, infectious diseases, transplants, and others.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

View All Listings